BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

...S.A.S., China Medical System Holdings Ltd. (HKEX:867) and Mediolanum...
BioCentury | Nov 18, 2016
Company News

Acticor, Mediolanum deal

...Acticor and Mediolanum partnered to develop Acticor’s acute ischemic stroke candidate ACT017 . Mediolanum will co-own...
...acquire marketing rights in two undisclosed European countries. Acticor received an undisclosed upfront payment from Mediolanum...
...inquiries. Acticor Biotech S.A.S., Paris, France Mediolanum Farmaceutici S.p.A. , Milan, Italy Business: Neurology Nora Weintraub ACT-017 Acticor Biotech Mediolanum...
BioCentury | Mar 2, 2015
Company News

Panoptes Pharma, Mediolanum Farmaceutici deal

...Panoptes granted Mediolanum rights to market PP-001 in two undisclosed European countries. Panoptes received an undisclosed...
...undisclosed development and sales milestones, plus royalties. Panoptes declined to disclose further financial terms, and Mediolanum...
...DHODH) is in preclinical testing to treat chronic uveitis. Panoptes Pharma GmbH , Vienna, Austria Mediolanum...
BioCentury | Jan 26, 2015
Financial News

Genenta Science completes venture financing

...therapy Date completed: 2015-01-23 Type: Venture financing Raised: EUR6.2 million ($7.2 million) Investors: Banca Esperia; Mediolanum...
BioCentury | May 13, 2013
Emerging Company Profile

Ultimovacs: hTERT redux

...trials to treat NSCLC and pancreatic cancer. Kael did not respond to requests for comment. Mediolanum...
...CSE:AFFI), Horsolm, Denmark Genovax s.r.l. , Turin, Italy Kael Co. Ltd. (KOSDAQ:082270), Daejon, South Korea Mediolanum...
BioCentury | Dec 10, 2012
Company News

Genovax, Mediolanum Farmaceutici deal

...Pharma Mediolanum acquired cancer vaccine GX301 from Genovax. Mediolanum will be responsible for developing and commercializing...
...is in preclinical testing to treat systemic lupus erythematosus (SLE). Genovax s.r.l. , Turin, Italy Mediolanum...
BioCentury | Mar 15, 2004
Company News

BioAlliance Pharma SA management update

...regulatory and pharmaceutical affairs and head of the nanotechnology business unit, formerly managing director at Mediolanum...
Items per page:
1 - 7 of 7
BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

...S.A.S., China Medical System Holdings Ltd. (HKEX:867) and Mediolanum...
BioCentury | Nov 18, 2016
Company News

Acticor, Mediolanum deal

...Acticor and Mediolanum partnered to develop Acticor’s acute ischemic stroke candidate ACT017 . Mediolanum will co-own...
...acquire marketing rights in two undisclosed European countries. Acticor received an undisclosed upfront payment from Mediolanum...
...inquiries. Acticor Biotech S.A.S., Paris, France Mediolanum Farmaceutici S.p.A. , Milan, Italy Business: Neurology Nora Weintraub ACT-017 Acticor Biotech Mediolanum...
BioCentury | Mar 2, 2015
Company News

Panoptes Pharma, Mediolanum Farmaceutici deal

...Panoptes granted Mediolanum rights to market PP-001 in two undisclosed European countries. Panoptes received an undisclosed...
...undisclosed development and sales milestones, plus royalties. Panoptes declined to disclose further financial terms, and Mediolanum...
...DHODH) is in preclinical testing to treat chronic uveitis. Panoptes Pharma GmbH , Vienna, Austria Mediolanum...
BioCentury | Jan 26, 2015
Financial News

Genenta Science completes venture financing

...therapy Date completed: 2015-01-23 Type: Venture financing Raised: EUR6.2 million ($7.2 million) Investors: Banca Esperia; Mediolanum...
BioCentury | May 13, 2013
Emerging Company Profile

Ultimovacs: hTERT redux

...trials to treat NSCLC and pancreatic cancer. Kael did not respond to requests for comment. Mediolanum...
...CSE:AFFI), Horsolm, Denmark Genovax s.r.l. , Turin, Italy Kael Co. Ltd. (KOSDAQ:082270), Daejon, South Korea Mediolanum...
BioCentury | Dec 10, 2012
Company News

Genovax, Mediolanum Farmaceutici deal

...Pharma Mediolanum acquired cancer vaccine GX301 from Genovax. Mediolanum will be responsible for developing and commercializing...
...is in preclinical testing to treat systemic lupus erythematosus (SLE). Genovax s.r.l. , Turin, Italy Mediolanum...
BioCentury | Mar 15, 2004
Company News

BioAlliance Pharma SA management update

...regulatory and pharmaceutical affairs and head of the nanotechnology business unit, formerly managing director at Mediolanum...
Items per page:
1 - 7 of 7